ArticleBiotechnology and bioengineering2026
Engineered B7-H3 Binding in Modular Gp2 Miniproteins.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
B7-H3, an important immune checkpoint modulator of T-cell function, is a tumor vasculature biomarker and is overexpressed in a variety of cancers. Its expression is associated with tumor growth, metastasis, and poor clinical prognosis, which makes B7-H3 an appealing target for diagnostics and therapeutics. High-affinity, specific, modular ligands are needed to achieve the various modes of molecular targeting strategies. A designed combinatorial library of the small (45 amino acid) Gp2 scaffold was sorted for binders to B7-H3 via yeast surface display with magnetic and flow cytometric cell sorting. Select variants were sequenced, characterized for binding affinity and specificity to B7-H3, and assessed for modularity in a protein-protein fusion. Protein ligands achieved single-digit nanomolar affinities and retained binding affinity upon conjugation, via a glycine-rich linker, to an enzyme. Directed evolution resulted in a potent, 0.7 nM binder with increased stability as assessed through the apparent midpoint of denaturation of 67°C. The engineered ligands provide small, modular, high-affinity B7-H3 binders for molecularly targeted therapeutics and diagnostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.